187 related articles for article (PubMed ID: 35159118)
1. Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.
Hallermayr A; Steinke-Lange V; Vogelsang H; Rentsch M; de Wit M; Haberl C; Holinski-Feder E; Pickl JMA
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159118
[TBL] [Abstract][Full Text] [Related]
2. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
3. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
5. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases.
Polivka J; Windrichova J; Pesta M; Houfkova K; Rezackova H; Macanova T; Vycital O; Kucera R; Slouka D; Topolcan O
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867151
[TBL] [Abstract][Full Text] [Related]
6. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
7. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
8. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management.
Wehrle J; Philipp U; Jolic M; Follo M; Hussung S; Waldeck S; Deuter M; Rassner M; Braune J; Rawluk J; Greil C; Waller CF; Becker H; Duque-Afonso J; Illert AL; Fritsch RM; Meiss F; Duyster J; von Bubnoff N; Scherer F
Diagnostics (Basel); 2020 Aug; 10(8):. PubMed ID: 32748806
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive Molecular Detection of Minimal Residual Disease in Papillary Thyroid Cancer Patients.
Almubarak H; Qassem E; Alghofaili L; Alzahrani AS; Karakas B
Front Oncol; 2019; 9():1510. PubMed ID: 31998653
[No Abstract] [Full Text] [Related]
10. Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer.
Gong J; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hendifar A; Osipov A; Zaghiyan K; Cho M; Gangi A; Hitchins M
Mol Clin Oncol; 2022 May; 16(5):100. PubMed ID: 35463213
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of
Kloten V; Rüchel N; Brüchle NO; Gasthaus J; Freudenmacher N; Steib F; Mijnes J; Eschenbruch J; Binnebösel M; Knüchel R; Dahl E
Oncotarget; 2017 Oct; 8(49):86253-86263. PubMed ID: 29156792
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review.
Schraa SJ; van Rooijen KL; Koopman M; Vink GR; Fijneman RJA
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565347
[TBL] [Abstract][Full Text] [Related]
15. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
[TBL] [Abstract][Full Text] [Related]
16. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Dec; 10(24):8820-8828. PubMed ID: 34821068
[TBL] [Abstract][Full Text] [Related]
17. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
[TBL] [Abstract][Full Text] [Related]
18. Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer.
Stasik S; Mende M; Schuster C; Mahler S; Aust D; Tannapfel A; Reinacher-Schick A; Baretton G; Krippendorf C; Bornhäuser M; Ehninger G; Folprecht G; Thiede C
Front Genet; 2021; 12():811291. PubMed ID: 35069704
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
20. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
